NGA Action Plan A3_1-v9-outlined

First Page		Document Content
Date: 2015-10-28 18:30:44 Medicine Clinical medicine Type I hypersensitivity Respiratory diseases RTT Allergology Medical emergencies Epinephrine autoinjector Anaphylaxis Autoinjector Allergy Epinephrine		NGA Action Plan A3_1-v9-outlined Add to Reading List Source URL: www.epiclub.co.nz Download Document from Source Website File Size: 276,11 KB Share Document on Facebook

	Sample Protocol for Treatment of Symptoms of Anaphylaxis Epinephrine Autoinjector Administration by School Health Professionals and Trained Personnel For School Age Children – Kindergarten - Grade 12 ARE SIGNS AND SYMP DocID: 1trOx - View Document
	NGA Action Plan A3_1-v9-outlined DocID: 1rm6O - View Document
	A severe allergic reaction can be life-threatening. When seconds count, don’t take the risk. For on-the-spot treatment DocID: 1rlnf - View Document
	PRESS RELEASE For Canadian media only Sanofi to Return Allerject® (epinephrine injection, USP) Rights to kaléo Laval, Qc. - February 23, Sanofi (EURONEXT : SAN and NYSE : SNY) announced today DocID: 1rewx - View Document
	Parent and Student Responsibilities for Life-Threatening Allergies (excerpt from the Hampton City Schools Life-Threatening Allergy Management Protocol) Parent/Guardian Responsibilities • Inform the school nurse/school DocID: 1qnWc - View Document